- Meeting abstract
- Open Access
L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery
© Current Science Ltd 1999
- Published: 2 March 1999
- Pulmonary Hypertension
- Congenital Heart Disease
- Cardiopulmonary Bypass
- Pulmonary Vascular Resistance
- Pulmonary Vasodilator
The increase in pulmonary vascular resistance (PVR) seen in children after cardiopulmonary bypass has been attributed to transient pulmonary endothelial dysfunction (PED). We therefore examined PED in children with congenital heart disease by assessing the L-arginine-nitric-oxide (NO) pathway in terms of substrate supplementation (L-arginine [L-Arg]), stimulation of endogenous nitric oxide release (substance P [Sub-P]), and end-product provision (inhaled NO) before and after open heart surgery.
Ten unoperated patients (0.62 ± 0.27 years) with pulmonary hypertension undergoing cardiac catheterisation, and 10 patients (0.64 ± 0.73 years) early after cardiopulmonary bypass were examined. All were sedated, paralysed and received positive pressure ventilation. Blood samples and pressure measurements were taken from catheters in the pulmonary artery and the pulmonary vein or left atrium. Respiratory mass spectrometry was used to measure oxygen uptake, and cardiac output was determined by the direct Fick method. PVR was calculated during steady state at ventilation with room air, during FiO2 = 0.65, and then during additional intravenous infusion of L-Arg (15 mg/kg/min), Sub-P (1 pmol/kg/min), and finally inhalation of NO (20 parts per million).
Postoperatively, the rise in PVR suggested pulmonary endothelial dysfunction restorable by L-Arg and Sub-P with no additional effect of inhaled NO. These results may indicate important new treatment strategies for these patients.